Novo Nordisk plans to make bariatric surgery a thing of the past: The key is not one but two drugs
Combinations of at least two different drugs have become an important element of Novo Nordisk's future plans within obesity, fatty liver disease and diabetes. One combination in particular looks set to become a top product, says chief science officer.
BY KEVIN GRØNNEMANN, TRANSLATED BY IDA JACOBSEN
For years, Novo Nordisk has dreamed of developing an obesity drug so effective that no one ever needs to undergo bariatric surgeries that shorten the gut and stomach permanently.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
